Company / Operating Income
Neurocrine Biosciences Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$619.1M
FY2025
5-year range
$102.5M / $619.1M
FY2021-FY2025
Trend
+8.5%
vs FY2024
Sector context
#14 of 204
Health Care
What the data says
Among 204 Health Care companies, Neurocrine Biosciences is in the top 7% for operating income. Operating Income has increased for 4 consecutive years, from $103M in FY2021 to $619M in FY2025.
Based on SEC 10-K filings.
$619M in FY2025 with a 5-year CAGR of +30.6%. Top quartile in the Health Care sector.
Improved from $251M to $619M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +56.0%
- 5-Year CAGR
- +30.6%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 204This company $619.1M Sector average $107.8M
▼
+474.6% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's operating income has grown for 4 consecutive years.
- 5-year CAGR of +30.6%, indicating consistent growth.
- In FY2025, operating income increased 8.5% year-over-year.
- Ranks #14 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $619.1M | +8.5% |
| FY2024 | $570.5M | +127.4% |
| FY2023 | $250.9M | +53.9% |
| FY2022 | $163.0M | +59.0% |
| FY2021 | $102.5M | -37.1% |
| FY2020 | $163.0M | +125.4% |
| FY2019 | $72.3M | +96.5% |
| FY2018 | $36.8M | +128.0% |
| FY2017 | -$131.4M | +10.9% |
| FY2016 | -$147.4M | -56.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026